AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1569238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 2997314 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran diet (normal daily intake + 78 gm wheat bran per day)
Number of subjects: 4
Study 2997314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose diet (normal daily intake + 30 gm cellulose per day)
Number of subjects: 4
Study 2997314 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet (normal daily intake)
Number of subjects: 4
Study 30383588 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal ART adherence
Number of subjects: 121
Study 30383588 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher motivation to adhere to ART
Number of subjects: 121
Study 30383588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower anticipated HIV-related stigma
Number of subjects: 121
Study 30383588 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to adhere to ART
Number of subjects: 121
Study 30203747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition therapy for observation group infants
Number of subjects: 2400
Study 30203747 — intervention group
Group type: COMPARATOR
Intervention: Normal neonates (reference group)
Number of subjects: 2400
Study 26571162 — intervention group
Group type: EXPERIMENTAL
Intervention: RAND
Number of subjects: 295
Study 26571162 — intervention group
Group type: EXPERIMENTAL
Intervention: OBS‐S
Number of subjects: 295
Study 26571162 — intervention group
Group type: COMPARATOR
Intervention: OBS‐NS
Number of subjects: 295
Study 25249158 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan (Farco-fill® Protect) as a liquid for inflation of catheter balloons
Number of subjects: 84
Study 25249158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 84
Study 22244635 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 91
Study 22244635 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite
Number of subjects: 91
Study 22244635 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite
Number of subjects: 91
Study 22244635 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1, n = 4)
Number of subjects: 91
Study 22244635 — intervention group
Group type: COMPARATOR
Intervention: Second control group (7 Eppendorf tubes)
Number of subjects: 91
Study 19844199 — intervention group
Group type: EXPERIMENTAL
Intervention: Half doses of PEG-ES and 12 tablets of 12 mg senna (HDG)
Number of subjects: 296
Study 19844199 — intervention group
Group type: COMPARATOR
Intervention: High-dose senna (SG)
Number of subjects: 296
Study 17272437 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 130
Study 17272437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 16227727 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 56
Study 16227727 — intervention group
Group type: COMPARATOR
Intervention: Other medications for ocular complications or pain relief
Number of subjects: 56
Study 12164986 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN‐HUT in older patients
Number of subjects: 324
Study 12164986 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN‐HUT in younger patients
Number of subjects: 324
Study 12164986 — intervention group
Group type: COMPARATOR
Intervention: GTN‐HUT in older controls
Number of subjects: 324
Study 12164986 — intervention group
Group type: COMPARATOR
Intervention: GTN‐HUT in younger controls
Number of subjects: 324
Study 10208190 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA albuterol
Number of subjects: 469
Study 10208190 — intervention group
Group type: COMPARATOR
Intervention: CFC albuterol
Number of subjects: 469
Study 7598140 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 58
Study 7598140 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE
Number of subjects: 58
Study 7598140 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT and ICE
Number of subjects: 58
Study 7598140 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 58
Study 7598140 — intervention group
Group type: COMPARATOR
Intervention: No specific therapy
Number of subjects: 58
Study 2190464 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IS-5-MN), 20 mg
Number of subjects: 10
Study 2190464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 688734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg N acetate and 50 μg EE2 (Minovlar)
Number of subjects: 6
Study 688734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.05 mg N (Noriday)
Number of subjects: 6
Study 688734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg N acetate and 50 μg EE2 (Gynovlar)
Number of subjects: 6
Study 688734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg N with 50 μg EE2 (intravenous preparation)
Number of subjects: 6
Study 30669713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-reality navigation combined with three-dimensional visualization technique
Number of subjects: 50
Study 30669713 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MR navigation or 3D visualization)
Number of subjects: 50
Study 29105558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5-2g/day
Number of subjects: 84
Study 29105558 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) 0.1mg/kg/day
Number of subjects: 84
Study 29105558 — intervention group
Group type: COMPARATOR
Intervention: Both MMF and TAC
Number of subjects: 84
Study 25418575 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behaviour Therapy (ICBT)
Number of subjects: 101
Study 25418575 — intervention group
Group type: COMPARATOR
Intervention: Control condition (received ICBT later)
Number of subjects: 101
Study 22972694 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus goserelin
Number of subjects: 197
Study 22972694 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus goserelin
Number of subjects: 197
Study 21377690 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual pharmacotherapy plus aerobic exercise (N = 22)
Number of subjects: 150
Study 21377690 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacotherapy (N = 11)
Number of subjects: 150
Study 19218270 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training group (n = 21)
Number of subjects: 32
Study 19218270 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 32
Study 19218270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Resistance training and Control)
Number of subjects: 32
Study 16995333 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg with ethanol (target plasma concentration 0.8 g/kg)
Number of subjects: 16
Study 16995333 — intervention group
Group type: COMPARATOR
Intervention: Almotriptan 12.5 mg alone
Number of subjects: 16
Study 12891200 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 100 IU/kg twice daily (n = 220)
Number of subjects: 438
Study 12891200 — intervention group
Group type: COMPARATOR
Intervention: Tinzaparin, 175 IU/kg once daily (n = 218)
Number of subjects: 438
Study 12891200 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 438
Study 12891200 — intervention group
Group type: COMPARATOR
Intervention: Tinzaparin
Number of subjects: 438
Study 12891200 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin and Tinzaparin
Number of subjects: 438
Study 10553855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILM)
Number of subjects: 20
Study 10553855 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laryngeal mask airway (LMA)
Number of subjects: 20
Study 10553855 — intervention group
Group type: COMPARATOR
Intervention: Control group (laryngoscope‐ and fiberscope‐guided oro/nasotracheal intubation)
Number of subjects: 20
Study 10999065 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid dysfunction (Hypothyroid, Hyperthyroid, probable Thyroiditis)
Number of subjects: 132
Study 1984900 — intervention group
Group type: EXPERIMENTAL
Intervention: Precordial echocardiography
Number of subjects: 93
Study 1984900 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography
Number of subjects: 93
Study 1984900 — intervention group
Group type: COMPARATOR
Intervention: Both echocardiographic techniques
Number of subjects: 93
Study 6624694 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine oral treatment (2 g/day)
Number of subjects: 14
Study 6624694 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14
Study 30803131 — intervention group
Group type: EXPERIMENTAL
Intervention: DFM30 (tinted daily SPF‐30 facial moisturizer)
Number of subjects: 33
Study 29274254 — intervention group
Group type: EXPERIMENTAL
Intervention: French Lyophilized Plasma (FLyP)
Number of subjects: 48
Study 29274254 — intervention group
Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 48
Study 27112783 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 10(6) IU interferon beta‐1b for 24 weeks
Number of subjects: 143
Study 27112783 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 × 10(6) IU interferon beta‐1b for 24 weeks
Number of subjects: 143
Study 27112783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 24224882 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary counseling to increase intake of unsaturated fatty acids
Number of subjects: 90
Study 24224882 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 90
Study 21544087 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg anthocyanins twice daily
Number of subjects: 31
Study 21544087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18629569 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of calcium plus 800 IU of vitamin D
Number of subjects: 242
Study 18629569 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg of calcium
Number of subjects: 242
Study 17244291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash and Counseling consumers (treatment group)
Number of subjects: 0
Study 17244291 — intervention group
Group type: COMPARATOR
Intervention: Medicaid services as usual (control group)
Number of subjects: 0
Study 16084855 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 10‐Hz repetitive transcranial magnetic stimulation to the left dorsolateral prefrontal cortex at 110% individual motor threshold
Number of subjects: 28
Study 16084855 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 28
Study 16084855 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Real and Sham)
Number of subjects: 28
Study 12105408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 14
Study 12105408 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 14
Study 10429745 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 0
Study 7589053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (suspended in water, 3 times a day)
Number of subjects: 12
Study 7589053 — intervention group
Group type: COMPARATOR
Intervention: Control (no cholestyramine)
Number of subjects: 12
Study 2695287 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ug ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Number of subjects: 192
Study 2695287 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 ug ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Number of subjects: 192
Study 2695287 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 ug ethinyl estradiol (EE) and 0.5 mg norethindrone (NE)
Number of subjects: 192
Study 2695287 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 192
Study 329422 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150‐200 mg daily)
Number of subjects: 26
Study 329422 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75‐100 mg daily)
Number of subjects: 26
Study 31306284 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Number of subjects: 1048
Study 31306284 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1048
Study 27869488 — intervention group
Group type: EXPERIMENTAL
Intervention: co-phenylcaine nasal spray
Number of subjects: 84
Study 27869488 — intervention group
Group type: COMPARATOR
Intervention: placebo nasal spray
Number of subjects: 84
Study 25381790 — intervention group
Group type: EXPERIMENTAL
Intervention: Index intervention (11 home visits, 2 antenatal and 9 postnatally)
Number of subjects: 167
Study 25381790 — intervention group
Group type: EXPERIMENTAL
Intervention: Index intervention delivered by trained NHS health visitors
Number of subjects: 167
Study 25381790 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal care)
Number of subjects: 167
Study 23348881 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing dry weight (ultrafiltration group)
Number of subjects: 0
Study 23348881 — intervention group
Group type: COMPARATOR
Intervention: Shorter dialysis treatment times
Number of subjects: 0
Study 23348881 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hours of delivered dialysis per session
Number of subjects: 0
Study 23348881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probing dry weight)
Number of subjects: 0
Study 21361808 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (strength training with Thera-Band resistive bands, 16 weeks, 3 times per week)
Number of subjects: 87
Study 21361808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 19213681 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy with zoledronic acid (4 mg IV every 6 months for 3 years)
Number of subjects: 1803
Study 19213681 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy without zoledronic acid
Number of subjects: 1803
Study 19213681 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg orally daily)
Number of subjects: 1803
Study 19213681 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (1 mg orally daily)
Number of subjects: 1803
Study 19213681 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy with zoledronic acid
Number of subjects: 1803
Study 17223994 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg mixed esters)
Number of subjects: 30
Study 17223994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone (200 mg nandrolone decanoate)
Number of subjects: 30
Study 17223994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml arachis oil vehicle)
Number of subjects: 30
Study 15154152 — intervention group
Group type: EXPERIMENTAL
Intervention: hands-on Reiki
Number of subjects: 46
Study 15154152 — intervention group
Group type: EXPERIMENTAL
Intervention: distance Reiki
Number of subjects: 46
Study 15154152 — intervention group
Group type: COMPARATOR
Intervention: distance Reiki placebo
Number of subjects: 46
Study 11700802 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic artificial tears (VAT) with sodium hyaluronate (0.4%, 0.25%) and chondroitin sulfate
Number of subjects: 28
Study 11700802 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride solution
Number of subjects: 28
Study 11700802 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic artificial tears (VAT)
Number of subjects: 28
Study 9150583 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived procedural fairness
Number of subjects: 0
Study 9150583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fairness heuristic theory
Number of subjects: 0
Study 9150583 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiments conducted
Number of subjects: 0
Study 8201953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) insulin delivery
Number of subjects: 10
Study 8201953 — intervention group
Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 10
Study 2740091 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir in modified aqueous cream (ACV-MAC)
Number of subjects: 0
Study 2740091 — intervention group
Group type: COMPARATOR
Intervention: Modified aqueous cream vehicle (control)
Number of subjects: 0
Study 129002 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80-160 mg/day)
Number of subjects: 12
Study 129002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30230409 — intervention group
Group type: EXPERIMENTAL
Intervention: Agilepristone (AGL) 10 mg/kg SC q24h for two consecutive days
Number of subjects: 28
Study 30230409 — intervention group
Group type: EXPERIMENTAL
Intervention: Agilepristone (AGL) + Misoprostol (MIS) 200 µg/cat PO q12h until abortion
Number of subjects: 28
Study 30230409 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (MIS) 200 µg/cat PO q12h until abortion
Number of subjects: 28
Study 30230409 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (MIS) 400 µg/cat PO q12h until abortion
Number of subjects: 28
Study 28493641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 802
Study 28493641 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 802
Study 28493641 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset AF
Number of subjects: 802
Study 28493641 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin and UFH (combined analysis)
Number of subjects: 802
Study 25957784 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus Sorafenib (n = 24)
Number of subjects: 50
Study 25957784 — intervention group
Group type: COMPARATOR
Intervention: TACE plus placebo (n = 26)
Number of subjects: 50
Study 24359514 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in neighbourhoods with moderate slope levels
Number of subjects: 11406
Study 24359514 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in neighbourhoods with higher slope levels
Number of subjects: 11406
Study 24359514 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of one percent in mean slope
Number of subjects: 11406
Study 21550205 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored for 7 days or less (fresh arm)
Number of subjects: 2510
Study 21550205 — intervention group
Group type: COMPARATOR
Intervention: Standard-issue RBCs stored, on average, 15 to 20 days (control arm)
Number of subjects: 2510
Study 19327412 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative coronary revascularization
Number of subjects: 101
Study 19327412 — intervention group
Group type: COMPARATOR
Intervention: No preoperative coronary revascularization
Number of subjects: 101
Study 19327412 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (no revascularization)
Number of subjects: 101
Study 19327412 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 101
Study 22352857 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care (MTFC)
Number of subjects: 166
Study 22352857 — intervention group
Group type: COMPARATOR
Intervention: Traditional community-based group care
Number of subjects: 166
Study 16048810 — intervention group
Group type: EXPERIMENTAL
Intervention: External Qi-therapy (QT)
Number of subjects: 40
Study 16048810 — intervention group
Group type: COMPARATOR
Intervention: Placebo control therapy
Number of subjects: 40
Study 12528607 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (200 micrograms daily)
Number of subjects: 150
Study 12528607 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 150
Study 9483167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.25 to 4 mg once daily)
Number of subjects: 412
Study 9483167 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (100 to 600 mg/day)
Number of subjects: 412
Study 9483167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 412
Study 9483167 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 412
Study 8568162 — intervention group
Group type: EXPERIMENTAL
Intervention: LCM 1010 (ready to use eye drops)
Number of subjects: 97
Study 8568162 — intervention group
Group type: COMPARATOR
Intervention: CBS 341A (eye drops to be reconstituted)
Number of subjects: 97
Study 2229496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine (EMLA) cream (n = 58)
Number of subjects: 83
Study 2229496 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (n = 25)
Number of subjects: 83
Study 629190 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant approach
Number of subjects: 27
Study 629190 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sensory integrative approach
Number of subjects: 27
Study 629190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both methods
Number of subjects: 27
Study 629190 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 27
Study 11413274 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg daily)
Number of subjects: 8
Study 11413274 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin (2000 mg daily)
Number of subjects: 8
Study 30635439 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased schooling duration due to policy reform
Number of subjects: 18929
Study 29572094 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC-AAT (4.0 mg/kg)
Number of subjects: 11
Study 29572094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26998949 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Nutrition Therapy and Exercise Regime (alternate weekly visits from a physical therapist and dietitian)
Number of subjects: 175
Study 26998949 — intervention group
Group type: COMPARATOR
Intervention: Social visits for 6 months (control group)
Number of subjects: 175
Study 26998949 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Nutrition Therapy and Exercise Regime
Number of subjects: 175
Study 25059701 — intervention group
Group type: EXPERIMENTAL
Intervention: CT table strap placed around the torso only (intervention group)
Number of subjects: 51